[先进疗法:克罗恩病医学治疗方案的最新进展]。

Deutsche medizinische Wochenschrift (1946) Pub Date : 2025-04-01 Epub Date: 2025-03-31 DOI:10.1055/a-2368-7173
Agnieszka Kafel, Clara Rodriguez de Castro Zalona, Chiara Seiz, Elisabeth Schnoy
{"title":"[先进疗法:克罗恩病医学治疗方案的最新进展]。","authors":"Agnieszka Kafel, Clara Rodriguez de Castro Zalona, Chiara Seiz, Elisabeth Schnoy","doi":"10.1055/a-2368-7173","DOIUrl":null,"url":null,"abstract":"<p><p>Crohn's disease is a chronic inflammatory bowel disease (IBD) that can manifest throughout the entire gastrointestinal tract from mouth to anus. It is characterized by so-called \"skip lesions\", which are affected sections of the intestine interspersed with healthy sections. In recent years, there have been significant progress and an expansion of medical treatment options for Crohn's disease with the approval of many new substances. Treatment goals have also become more ambitious, going beyond clinical symptom control to mucosal healing and, according to the STRIDE II criteria, to transmural healing in Crohn's disease in the future. If these goals are achieved, patients with Crohn's disease have a good chance of remaining in long-term remission and can expect fewer complications such as disease progression, hospitalization, anemia, fistulas, strictures, or surgeries. Despite having access to a variety of different substance classes in the treatment of Crohn's disease, in everyday practice we can see that these medications are not effective for some patients in the long-term. There is a so-called \"therapeutic ceiling\" in IBD, meaning that only about 40-50% of those affected are successfully managed long-term with one substance. Therefore, new medical treatment options for Crohn's disease always represent an opportunity to treat patients even better.</p>","PeriodicalId":93975,"journal":{"name":"Deutsche medizinische Wochenschrift (1946)","volume":"150 8","pages":"405-411"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Advanced therapies: Un update on medical treamtent options in Crohn`s disease].\",\"authors\":\"Agnieszka Kafel, Clara Rodriguez de Castro Zalona, Chiara Seiz, Elisabeth Schnoy\",\"doi\":\"10.1055/a-2368-7173\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Crohn's disease is a chronic inflammatory bowel disease (IBD) that can manifest throughout the entire gastrointestinal tract from mouth to anus. It is characterized by so-called \\\"skip lesions\\\", which are affected sections of the intestine interspersed with healthy sections. In recent years, there have been significant progress and an expansion of medical treatment options for Crohn's disease with the approval of many new substances. Treatment goals have also become more ambitious, going beyond clinical symptom control to mucosal healing and, according to the STRIDE II criteria, to transmural healing in Crohn's disease in the future. If these goals are achieved, patients with Crohn's disease have a good chance of remaining in long-term remission and can expect fewer complications such as disease progression, hospitalization, anemia, fistulas, strictures, or surgeries. Despite having access to a variety of different substance classes in the treatment of Crohn's disease, in everyday practice we can see that these medications are not effective for some patients in the long-term. There is a so-called \\\"therapeutic ceiling\\\" in IBD, meaning that only about 40-50% of those affected are successfully managed long-term with one substance. Therefore, new medical treatment options for Crohn's disease always represent an opportunity to treat patients even better.</p>\",\"PeriodicalId\":93975,\"journal\":{\"name\":\"Deutsche medizinische Wochenschrift (1946)\",\"volume\":\"150 8\",\"pages\":\"405-411\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Deutsche medizinische Wochenschrift (1946)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2368-7173\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche medizinische Wochenschrift (1946)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2368-7173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

克罗恩病是一种慢性炎症性肠病(IBD),可表现为从口腔到肛门的整个胃肠道。它的特点是所谓的“跳跃病变”,即受影响的肠道部分穿插着健康的肠道部分。近年来,随着许多新物质的批准,克罗恩病的医疗选择已经取得了重大进展和扩大。治疗目标也变得更加雄心勃勃,从临床症状控制到粘膜愈合,并根据STRIDE II标准,在未来实现克罗恩病的跨壁愈合。如果达到这些目标,克罗恩病患者就有很好的机会保持长期缓解,并且可以预期更少的并发症,如疾病进展、住院、贫血、瘘管、狭窄或手术。尽管在克罗恩病的治疗中有多种不同的药物类别,但在日常实践中,我们可以看到这些药物对一些患者长期无效。在IBD中存在所谓的“治疗上限”,这意味着只有大约40-50%的患者能够成功地长期使用一种药物。因此,克罗恩病的新治疗方案总是代表着更好地治疗患者的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Advanced therapies: Un update on medical treamtent options in Crohn`s disease].

Crohn's disease is a chronic inflammatory bowel disease (IBD) that can manifest throughout the entire gastrointestinal tract from mouth to anus. It is characterized by so-called "skip lesions", which are affected sections of the intestine interspersed with healthy sections. In recent years, there have been significant progress and an expansion of medical treatment options for Crohn's disease with the approval of many new substances. Treatment goals have also become more ambitious, going beyond clinical symptom control to mucosal healing and, according to the STRIDE II criteria, to transmural healing in Crohn's disease in the future. If these goals are achieved, patients with Crohn's disease have a good chance of remaining in long-term remission and can expect fewer complications such as disease progression, hospitalization, anemia, fistulas, strictures, or surgeries. Despite having access to a variety of different substance classes in the treatment of Crohn's disease, in everyday practice we can see that these medications are not effective for some patients in the long-term. There is a so-called "therapeutic ceiling" in IBD, meaning that only about 40-50% of those affected are successfully managed long-term with one substance. Therefore, new medical treatment options for Crohn's disease always represent an opportunity to treat patients even better.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信